Movers and SHAKERS
Tuesday, June 11, 2019
Choppy Waters for electroCore
electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- CEO Frank Amato Departs. Yesterday, electroCore announced another departure from the leadership team since the annual shareholder meeting held on June 7, 2019. Frank R. Amato is leaving the company after serving as a Chief Executive Officer since 2016. He will continue to serve as the CEO and board member until a new CEO is recruited. This position is expected to be filled before September 30, 2019.
- Restructuring Continues.We expect the company to pursue additional steps to reshape the leadership team following two departures within the past week. Besides Frank’s departure...
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.